Home | Site Map | Useful Resource | Search:  
Veeda Oncology Experience - Veeda Oncology
 
 
About Us . Experience . Phase I trials . Access to Oncology Patients . Services . Investigative Site Sign-up . Careers
  Experience
Tumor Experience
Case Studies
 
  Quick Links
 
 
 
Home > Experience > Oncology Tumor Experience
 

Oncology Tumor Experience
77 Oncology trials conducted since 2001
Total of 6,585 patients accrued
Tumor Types include:
  Breast
  CLL (Chronic Lymphocytic Leukemia)
  NSCLC (Non Small Cell Lung Cancer)
  Non Hodgkin’s Lymphoma
  Colorectal
  Hodgkin’s Lymphoma
  Prostate
  Melanoma
  SCLC (Small Cell Lung Cancer)
  Multiple Myeloma
  Renal
  MDS (Myelodysplastic Syndrome)
  Head & Neck Cancer
  Glioblastoma
  Bone Mets
  Ovarian
Tumor Experience
 
CANCER Phase Number of Patients Number of Sites Year Started Year Completed
AML II 40 5 2001 2003
Breast--1st line Met IV 300 70 2001 2004
Breast--1st line Met II 51 21 2003 2007
Breast--1st line Met II 72 29 2005 2008
Breast--Adjuvant ER+ III 117 8 2006 2008
Breast--2nd line Met III 7 3 2006 2008
Breast--1st line Met III 17 7 2006 2007
Breast--1st line Met II 16 15 2007 2008
Breast--1st line Met II 32 14 2008 Ongoing
Breast--1st/2nd line Met II 5 5 2008 2009
Breast--Adjuvant IV 49 9 2008 2009
Breast--1st/2nd line Erb2+ II 10 9 2008 Ongoing
Breast--2nd line ER+ III 0 7 2009 Pending
Breast--1st line HER+ III 4 8 2009 Pending
Ovarian--2nd Line II 4 5 2008 2009
NSCLC (Non Small Cell Lung Cancer) II b 110 20 2003 2005
Lung Epidemiology 3000 65 2006 Ongoing
NSCLC (Non Small Cell Lung Cancer) -- 1st line II 82 21 2004 2008
NSCLC (Non Small Cell Lung Cancer) -- 2nd line II 7 9 2004 2006
NSCLC (Non Small Cell Lung Cancer) -- 1st line II 69 22 2005 2007
NSCLC (Non Small Cell Lung Cancer) -- 2nd line II 70 15 2005 2007
NSCLC (Non Small Cell Lung Cancer) -- 1st line III 15 4 2006 2008
NSCLC (Non Small Cell Lung Cancer) -- Advanced II 10 8 2007 2008
NSCLC (Non Small Cell Lung Cancer) -- 1st line II 83 18 2006 Ongoing
NSCLC (Non Small Cell Lung Cancer) -- 2nd/3rd line III 10 8 2007 Ongoing
NSCLC (Non Small Cell Lung Cancer) -- 2nd line III 7 9 2008 Ongoing
NSCLC (Non Small Cell Lung Cancer) -- 1st line III 0 3 2009 Pending
NSCLC (Non Small Cell Lung Cancer) -- 1st line III 0 11 2009 Ongoing
NSCLC (Non Small Cell Lung Cancer) -- 1st line III 32 15 2009 Ongoing
NSCLC (Non Small Cell Lung Cancer) -- 2nd line III 14 9 2009 Ongoing
NSCLC (Non Small Cell Lung Cancer)-1st line with Radiation III 0 111 2009 Ongoing
NSCLC (Non Small Cell Lung Cancer) - 1st line III 11 8 2008 Ongoing
SCLC (Small Cell Lung Cancer)-2nd line III 36 11 2008 Ongoing
SCLC (Small Cell Lung Cancer)-1st line I 34 14 2008 Ongoing
Rectum II 87 16 2003 2008
Colorectal--1st line II 82 19 2004 2008
Colorectal--1st line III 57 31 2005 2007
Colorectal--2nd line II 39 15 2006 2007
Colorectal--1st line IIb 31 9 2008 Ongoing
Colorectal--2nd line II 2 3 2008 Ongoing
Colorectal--1st line II 6 6 2008 2009
Colorectal--1st line II 0 4 2009 Ongoing
Pancreatic--1st line II 8 20 2003 2004
Prostate Ia 65 5 2008 2009
Prostate IV 79 12 2004 Ongoing
Prostate IV 160 50 2003 2006
Prostate Epidemiology 120 1 2007 2008
Prostate II a 80 6 2007 Ongoing
Prostate III a 250 50 2002 2004
HRPC--1st line II 35 22 2006 2008
HRPC--1st line II 11 10 2007 2007
HRPC--2nd line and beyond EAP 40 16 2007 2007
Kidney I 10 5 2004 2007
Kidney Epidemiology 35 1 2008 2008
Renal cell--1st line III 45 8 2006 2008
Renal cell--1st line III 6 6 2008 Ongoing
Renal cell--1st line III 6 3 2009 Ongoing
Hodgkin’s Lymphoma I 18 1 2006 Ongoing
Hodgkin’s Lymphoma I 12 1 2007 2009
NHL III 320 42 2007 2008
CLL (Chronic Lymphocytic Leukemia) IV 210 25 2007 2007
Mantle Cell Lymphoma –2nd line II 8 25 2008 Ongoing
MDS (Myelodysplastic Syndrome) -- 1st line II 15 13 2004 2006
MDS (Myelodysplastic Syndrome) -- 1st line III 0 5 2009 Ongoing
Biliary tract II 61 6 2003 2007
Melano-carcinoma II a 152 2 2007 2008
Melanoma--1st line II 11 5 2007 2008
Head & Neck Cancer Investigator-initiated study 75 1 2007 Ongoing
Glioblastoma IV 150 12 2000 2004
Multiple Myeloma--1st line III 30 17 2007 Ongoing
Myeloma I 36 3   Ongoing
Myeloma IV 550 82   Ongoing
Myeloma IV 300 60 2001 2003
Breast, NSCLC (Non Small Cell Lung Cancer), Colon--Supportive care Antiemetic II 33/16 14 2006 2007
Breast--Supportive care
Bone Mets		 III 3 12 2006 2007
Bone Mets--Supportive care III 23 8 2006 2008
Non SCLC (Small Cell Lung Cancer)--Supportive care Cancer Cachexia II 50 13 2008 Ongoing
 
To know more about Veeda services or if you have any query please click here to contact us
 
To know more how veeda’s expertise and experience for Tumor can help you, please be in touch with us using this form
 
Download PDF
 
 
India - IST  IST Time Here Belgium - CET  CET Time Here
       
USA - EST  EST Time Here
 
Disclaimer | © Veeda Clinical Research Limited
Veeda Clinical Research and Veeda Oncology are registered trademarks of Veeda Clinical Research, Inc.